HK1207871A1 - Peptides derived from viral proteins for use as immunogens and dosage reactants - Google Patents

Peptides derived from viral proteins for use as immunogens and dosage reactants Download PDF

Info

Publication number
HK1207871A1
HK1207871A1 HK15108544.7A HK15108544A HK1207871A1 HK 1207871 A1 HK1207871 A1 HK 1207871A1 HK 15108544 A HK15108544 A HK 15108544A HK 1207871 A1 HK1207871 A1 HK 1207871A1
Authority
HK
Hong Kong
Prior art keywords
immunogens
reactants
dosage
viral proteins
peptides derived
Prior art date
Application number
HK15108544.7A
Other languages
English (en)
Chinese (zh)
Inventor
Birger SØRENSEN
Mats ÖKVIST
Arnt Ove HOVDEN
Maja Sommerfelt GRØNVOLD
Original Assignee
Bionor Immuno As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno As filed Critical Bionor Immuno As
Publication of HK1207871A1 publication Critical patent/HK1207871A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
HK15108544.7A 2012-06-06 2013-06-06 Peptides derived from viral proteins for use as immunogens and dosage reactants HK1207871A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656256P 2012-06-06 2012-06-06
US61/656,256 2012-06-06
PCT/EP2013/061751 WO2013182661A1 (en) 2012-06-06 2013-06-06 Peptides derived from viral proteins for use as immunogens and dosage reactants

Publications (1)

Publication Number Publication Date
HK1207871A1 true HK1207871A1 (en) 2016-02-12

Family

ID=48577073

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108544.7A HK1207871A1 (en) 2012-06-06 2013-06-06 Peptides derived from viral proteins for use as immunogens and dosage reactants

Country Status (15)

Country Link
US (1) US10501499B2 (enExample)
EP (1) EP2859011B1 (enExample)
JP (1) JP6310909B2 (enExample)
KR (1) KR20150018870A (enExample)
CN (1) CN104619718A (enExample)
AU (1) AU2013273482A1 (enExample)
BR (1) BR112014030466A2 (enExample)
CA (1) CA2874923C (enExample)
EA (1) EA201492262A1 (enExample)
HK (1) HK1207871A1 (enExample)
IL (1) IL235891A0 (enExample)
IN (1) IN2014KN02769A (enExample)
MX (1) MX2014014683A (enExample)
NZ (1) NZ702146A (enExample)
WO (1) WO2013182661A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2950785A4 (en) * 2013-02-04 2016-09-21 Univ Notre Dame Du Lac NANOPARTICLE-drug delivery systems
SG11201701565PA (en) 2014-09-03 2017-03-30 Immunogen Inc Conjugates comprising cell-binding agents and cytotoxic agents
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
MY189551A (en) * 2016-06-20 2022-02-16 Isa Pharmaceuticals B V Formulation of a peptide vaccine
WO2018127689A1 (en) * 2017-01-03 2018-07-12 Emergex Vaccines Holdings Ltd Universal influenza vaccine compositions
CN110548136A (zh) * 2018-05-30 2019-12-10 王美亮 汉坦病毒长肽疫苗
US11203614B2 (en) * 2019-03-25 2021-12-21 Immunwork Inc. Composite polypeptide having a metal binding motif and molecular construct comprising the same
KR102393872B1 (ko) * 2019-08-28 2022-05-04 엠브릭스 주식회사 바이러스 외피를 손상시키는 m2 단백질 유래 항바이러스 펩타이드 및 그의 용도
US20230109142A1 (en) * 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
KR102707584B1 (ko) * 2020-04-02 2024-09-19 조선대학교산학협력단 코로나바이러스 감염증­１９의 진단 및 백신을 위한 재조합 뉴클레오캡시드 단백질 및 이의 용도

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
MX9204376A (es) 1991-07-25 1993-02-01 Idec Pharma Corp Composiciones y metodos para inducir respuestas citotoxicas de los linfocitos t.
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
EP0835663B1 (en) 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Combined vaccines comprising Hepatitis B surface antigen and other antigens
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
PT735893E (pt) 1993-09-14 2009-03-06 Pharmexa Inc Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
DE69432475T2 (de) 1993-11-04 2004-03-04 Innogenetics N.V. Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU697171B2 (en) 1994-04-08 1998-10-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis C virus core peptide for stimulation of cytotoxic T lymphocytes and diagnosis of HCV exposure
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU2658897A (en) 1996-03-21 1997-10-10 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
ES2251028T3 (es) 1996-05-24 2006-04-16 Chiron Corporation Proteina de fusion de epitopos multiples.
US6566330B1 (en) 1996-10-22 2003-05-20 Medical University Of South Carolina Foundation Research Development Positively charged non-natural amino acids, methods of making and using thereof in peptides
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
PL202399B1 (pl) 1998-10-05 2009-06-30 Pharmexa As Zastosowanie adiuwanta i pierwszego analogu polipeptydowego antygenu związanego z komórką lub co najmniej jednego fragmentu kwasu nukleinowego kodującego epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką lub niepatogennego mikroorganizmu lub wirusa, który niesie fragment kwasu nukleinowego, który koduje i wyraża co najmniej jeden epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką, sposób selekcji immunogennego analogu antygenu polipeptydowego związanego z komórką, sposób wytwarzania komórki wytwarzającej analog an
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
AU6226100A (en) 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US20020076415A1 (en) 1999-12-14 2002-06-20 Jing-Hsiung Ou Hepatitis C virus gene products
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
JP2004522415A (ja) 2000-09-01 2004-07-29 エピミューン インコーポレーティッド Ｈｌａ結合ペプチドおよびその使用方法
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
EP1195381A1 (de) 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
GB0026094D0 (en) 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
US7702465B2 (en) 2002-06-10 2010-04-20 Algonomics N.V. Method, computing routine, device for predicting properties of MHC/peptide complexes, and data and peptides produced therefrom
EP1543039B1 (en) * 2002-08-12 2011-07-13 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
EP2402026A3 (en) 2002-09-13 2012-04-18 Intercell AG Method for isolating hepatitis C virus peptides
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
EP1652858A1 (en) 2004-10-28 2006-05-03 Innogenetics N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
CA2587589A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
WO2008107400A1 (en) * 2007-03-02 2008-09-12 Genimmune N.V. Hcv polyepitope construct and uses thereof
WO2011000962A2 (en) 2009-07-03 2011-01-06 Bionor Immuno As Novel therapeutic and diagnostic means
WO2012072088A1 (en) 2010-12-02 2012-06-07 Bionor Immuno As Peptide scaffold design
WO2012092934A1 (en) 2011-01-06 2012-07-12 Bionor Immuno As Monomeric and multimeric immunogenic peptides
US8618303B2 (en) * 2011-01-07 2013-12-31 Hoffmann-La Roche Inc. Pyrrolidine derivatives

Also Published As

Publication number Publication date
AU2013273482A1 (en) 2014-12-11
JP2015521206A (ja) 2015-07-27
IL235891A0 (en) 2015-01-29
US10501499B2 (en) 2019-12-10
WO2013182661A1 (en) 2013-12-12
KR20150018870A (ko) 2015-02-24
IN2014KN02769A (enExample) 2015-05-08
CA2874923C (en) 2021-08-31
NZ702146A (en) 2016-11-25
EA201492262A1 (ru) 2015-08-31
JP6310909B2 (ja) 2018-04-11
BR112014030466A2 (pt) 2017-09-12
EP2859011B1 (en) 2019-12-11
CA2874923A1 (en) 2013-12-12
US20150152140A1 (en) 2015-06-04
EP2859011A1 (en) 2015-04-15
MX2014014683A (es) 2015-02-24
CN104619718A (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EA201390806A1 (ru) Конструкция пептидного каркаса
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
PH12015501017A1 (en) Alternative uses for hbv assembly effectors
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2013040492A3 (en) Methods for treating hcv
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
WO2013014294A3 (en) Improved baculovirus expression systems
WO2015052543A3 (en) Malaria vaccination
MX346475B (es) Peptidos inmunogenicos monomericos y multimericos.
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
EA201001045A1 (ru) Модифицированный вирус гриппа
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
WO2015058772A3 (en) Novel hcv culture systems and direct-acting antiviral sensitivity
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
BR112017006680A2 (pt) variantes de vírus influenza a
PH12014502551B1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
PH12014500369A1 (en) Influenza h5 vaccines
MX360161B (es) Proceso para preparar compuestos antiviricos.
WO2013055326A3 (en) Vaccines for human papilloma virus and methods for using the same
MX2019007924A (es) Vacunas contra la influenza.
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
WO2014008475A3 (en) Compositions and methods related to viral vaccines
MY199945A (en) Vaccines against infectious diseases caused by positive stranded rna viruses